We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical industry to China. Though we have long stood as the global leader in ...

The convergence of AI with biotechnology has ushered in an era of innovation in drug development, genomics, and diagnostics.

The opportunities I had as an aspiring researcher are gone. The path to a better life for kids in Sacramento is slipping away ...

Fidelity Advisor Biotechnology Fund earns an Average Process Pillar rating. The main driver of the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's ...

The Biotechnology Risk Assessment Grants (BRAG) program supports the development of new information that will assist federal regulatory agencies in making evidence-based decisions about the ...

The National Biotechnology Initiative Act of 2025, legislation that would implement key recommendations of the report, was introduced earlier this month in the House and the Senate by the commission’s ...

Vir Biotechnology, Inc. (Nasdaq: VIR) ... In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur.

The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...

The National Security Commission on Emerging Biotechnology (NSCEB) announced on April 8, 2025, the availability of its final report and action plan, “urging Congressional action to bring the ...

Fidelity Select Biotechnology Portfolio earns an Average Process Pillar rating. The predominant contributor to the rating is its parent firm's superior long-term risk-adjusted performance, as ...